| Bioactivity | Naratuximab emtansine (IMGN529) is a CD37-targeted ADC consisting of a humanized IgG1 mAb coupled to the microtubule disruptor DM1. Naratuximab emtansine has high affinity and specificity for CD37, allowing ADC internalization, processing and intracellular release of DM1. Due to its ability to disrupt microtubule assembly, DM1 can subsequently induce cell cycle arrest and apoptosis[1]. |
| Invitro | Naratuximab emtansine (IMGN529) (0.125 nM, 24 h) 单独治疗可诱导DLBCL细胞系中半胱氨酸 3/7 的激活，在 rituximab（2 nM）存在的情况下，这种效果明显增强，进一步诱导裂解的 PARP 水平增加[1]。Naratuximab emtansine（IMGN529）（0-3 ng/mL）对 U-2932 和 SU-DHL-4 细胞系显示出剂量依赖性抗体依赖的细胞介导的细胞毒性（ADCC）活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Naratuximab emtansine 相关抗体: |
| In Vivo | Naratuximab emtansine（IMGN529）（10 毫克/公斤，单次注射）单次治疗对 U-2932 肿瘤无活性，当与 rituximab 联合使用时，显著增强了抗肿瘤活性，且在研究过程中没有观察到 U2932 雌性 CB.17-SCID 小鼠有明显的毒性或体重减轻[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 1607824-64-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Stuart W Hicks, et al. The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models. Neoplasia. 2017 Sep;19(9):661-671. |